Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 235 results for radiotherapy

  1. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046

    Awaiting development [GID-TA11335] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Patient decision aids

    of cancer in people with a family history of breast cancer Intrabeam radiotherapy for treating early breast cancer Cardiovascular...

  3. The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised

    Medtech innovation briefing
    Published
    16 December 2014

  4. Axumin for functional imaging of prostate cancer recurrence (MIB172)

    NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .

    Medtech innovation briefing
    Published
    8 February 2019

  5. Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)

    Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.

    Technology appraisal guidance
    Published
    18 August 2021
    View recommendations

    Sections for TA720

  6. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

    Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.

    Technology appraisal guidance
    Published
    23 January 2013
    View recommendations

    Sections for TA272

  7. Low dose rate brachytherapy for localised prostate cancer (IPG132)

    Evidence-based recommendations on low dose rate brachytherapy for localised prostate cancer. This involves placing small radioactive seeds into the prostate that give off low doses of radiation to destroy cancer cells.

    Interventional procedures guidance
    Published
    27 July 2005
    View recommendations

    Sections for IPG132

  8. Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)

    Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over.

    Technology appraisal guidance
    Published
    29 May 2024
    View recommendations

    Sections for TA977

  9. Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary, can radiotherapy target volumes be selected based on clinical and pathological factors?

    aerodigestive tract origin:- In people with CUADT of unknown primary, can radiotherapy target volumes be selected based on clinical and...

    Research recommendation
    Published
    6 April 2016

  10. Preoperative high dose rate brachytherapy for rectal cancer (IPG531)

    Evidence-based recommendations on preoperative high dose rate brachytherapy for rectal cancers. This involves inserting an applicator into the rectum and using it to deliver radiation to the tumour.

    Interventional procedures guidance
    Published
    26 August 2015
    View recommendations

    Sections for IPG531

  11. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

    Clinical guideline
    Published
    27 June 2007
    View recommendations

    Sections for CG49

  12. Managing glioma: management of IDH wildtype grade II glioma:- Does the addition of concurrent and adjuvant temozolomide to radiotherapy improve overall survival in patients with IDH wildtype grade II glioma?

    glioma:- Does the addition of concurrent and adjuvant temozolomide to radiotherapy improve overall survival in patients with IDH...

    Research recommendation
    Published
    11 December 2018

  13. Stent placement for vena caval obstruction (IPG79)

    Evidence-based recommendations on stent placement for vena caval obstruction. This involves using a catheter to position a stent, which may be self-expanding or balloon-dilated, across the area of narrowing to relieve it.

    Interventional procedures guidance
    Published
    28 July 2004
    View recommendations

    Sections for IPG79

  14. Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (IPG484)

    Evidence-based recommendations on transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. This involves using a laser to cut out the tumour and a small amount of the healthy flesh around it.

    Interventional procedures guidance
    Published
    27 March 2014
    View recommendations

    Sections for IPG484

  15. Is symptom-based review as effective as scheduled follow-up for people treated with radical cystectomy or radical radiotherapy for organ-confined, muscle-invasive bladder cancer? Outcomes of interest are overall survival, health-related quality of life, resource use and cost.

    scheduled follow-up for people treated with radical cystectomy or radical radiotherapy for organ-confined, muscle-invasive bladder...

    Research recommendation
    Published
    9 June 2015